Thymosin Alpha-1
Also known as: Thymalfasin (trade name Zadaxin)
Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) approved as Zadaxin in 35+ countries for chronic hepatitis B/C and as an immune adjuvant. It is NOT FDA-approved in the US.
Pricing for Thymosin Alpha-1
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Thymosin Alpha-1
67 third-party tests across 19 vendors. Each card links to the full report.
For
Thymosin Alpha-1
by Verified Peptides· batch TA05260910H
For
Thymosin Alpha-1
by Skye Peptides· batch TA126-10-001
For
Thymosin Alpha-1
by Real Peptides· batch Black Cap
For
Thymosin Alpha-1
by Riptide Wellness· batch RWTA1-10-1003
For
Thymosin Alpha-1
by Peptide Supply Co.· batch TA1004132026
For
Thymosin Alpha-1
by OROS Research· batch OR-LPTA5-326-B1
For
Thymosin
by Verified Peptides· batch cmojb57q300trkirxximley58
For
Thymosin Alpha-1
by Amino Club· batch THA0001
For
Thymosin alpha-1
by Ion Peptide· batch TA110-03232026
For
Thymosin Alpha-1
by Profound Aminos· batch cmojb89io01hzkirx1zv5axqw
For
Thymosin Alpha-1
by Verified Peptides· batch TA032608106
For
Thymosin Alpha-1
by Peptide Partners· batch TA202602
For
Thymosin Alpha-1
by Glacier Aminos· batch TA10GA-03
For
Thymosin Alpha-1
by Crush Research· batch CR-TAT10-0212-1
For
Thymosin Alpha-1
by Ion Peptide· batch TA110-02122026
For
Thymosin Alpha-1
by Peptide Supply Co.· batch PSCTA110001
For
Thymoген
by BioLongevity Labs· batch 44-3-46035
For
Thymosin Alpha-1
by MedGe Peptides· batch TAL10LT12
For
Thymosin Alpha-1
by MedGe Peptides· batch TAL10LT12
For
Thymosin Alpha-1
by Simple Peptide· batch TIMAG10/2026-J
For
Thymosin Alpha-1
by Glacier Aminos· batch TA10GA02
For
Thymosin Alpha-1
by Ion Peptide· batch TA10-122025
For
Thymosin Alpha-1
by Ion Peptide· batch TA15-122825
For
Thymosin Alpha-1
by Verified Peptides· batch 12-25-0710F
28 citations indexed for Thymosin Alpha-1
rct · 2027
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway.
Study · 2026
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
review · 2026
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation
Thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalization with standard hormone replacement, prompting investigation into adjunctive strategies that target immune, metabolic, and neuroendocrine con…
Study · 2026
The significance of thymosin α1 and intravenous immunoglobulin in the prevention of pulmonary adverse events in B-cell lymphoma treated with R-CHOP: A prospective study
Abstract Background Rituximab based chemotherapy regimens, particularly R-CHOP, are highly effective for the treatment of B-cell lymphoma (BCL) but are frequently complicated by pulmonary adverse effects (PAEs) that may disrupt therapy and adversely affect outcomes.
Study · 2026
Oncogenes and tumor suppressor genes are enriched in stop-loss mutations generating protein extensions
ABSTRACT Cancer genomes tend to accumulate a large number of mutations, and even rare mutations such as those causing the loss of a stop codon can be observed in a significant fraction of the tumors.
Study · 2026
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8<sup>+</sup> T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
Background and aim CD8 + T cell immunosenescence drives hepatocellular carcinoma (HCC) progression and impedes therapeutic efficacy.